Umeå University's logo

umu.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Reforming the Swedish pharmaceuticals market: Consequences for costs per defineddaily dose
Södertörns högskola, Huddinge, Sweden; HUI Research, Stockholm, Sweden.ORCID-id: 0000-0001-5026-9479
Umeå universitet, Samhällsvetenskapliga fakulteten, Handelshögskolan vid Umeå universitet, Nationalekonomi.ORCID-id: 0000-0003-4467-8676
Dalarna University, Sweden; HUI Resarch, Stockholm, Sweden.
2014 (engelsk)Rapport (Annet vitenskapelig)
Abstract [en]

In 2009, the Swedish pharmaceuticals market was reformed. One of the stated policygoals was to achieve low costs for pharmaceutical products dispensed in Sweden.

Prices and sales data for off-patent brand-name and generic pharmaceuticals have beencollected, and a log-linear regression model was used to estimate how the policy changes affected thecost per defined daily dose.

The estimated effect is a 19 percent cost reduction per defined daily dose at the retail leveland a 35 percent reduction in the prices at the wholesale level (pharmacies' purchase prices). Theempirical results suggest that half of the retail-level price reduction is due to the introduction of a pricecap for products going off patent and half is due to other components of the reform. Measured at thewholesale level the latter effect is larger than the former.

The reforms reduced the cost per defined daily dose for consumers while beingadvantageous also for the pharmacies, who saw their retail margins increase due to the reform.However, pharmaceutical firms supplying off-patent pharmaceuticals experienced a clear reduction inthe price received for their products.

sted, utgiver, år, opplag, sider
Stockholm: HUI Research , 2014. , s. 14
Serie
HUI Working Papers ; 105
Emneord [en]
Pharmaceutical industry, national pharmacy monopoly, pharmacy deregulation, competition, generics, pricing
HSV kategori
Forskningsprogram
Politik, ekonomi och samhällets organisering
Identifikatorer
URN: urn:nbn:se:umu:diva-219663OAI: oai:DiVA.org:umu-219663DiVA, id: diva2:1828778
Forskningsfinansiär
Swedish Competition AuthorityTilgjengelig fra: 2024-01-17 Laget: 2024-01-17 Sist oppdatert: 2024-01-18bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Fulltext

Person

Bergman, MatsGranlund, David

Søk i DiVA

Av forfatter/redaktør
Bergman, MatsGranlund, David
Av organisasjonen

Søk utenfor DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric

urn-nbn
Totalt: 30 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf